1 / 7

Supplementary Table 1 - Shah et al

Supplementary Table 1 - Shah et al. Supplementary table 1 (continued) - Shah et al.

elvis-morin
Télécharger la présentation

Supplementary Table 1 - Shah et al

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplementary Table 1 - Shah et al

  2. Supplementary table 1 (continued) - Shah et al Supplementary Table 1. miRNA profiling of AML cells in response lentiviral NRF2 knockdown and treatment with the NRF2 activator sulforaphane. THP-1 cells were either transduced with NEG (NEG-KD) and NRF2 (NRF2-KD) targeted miRNA lentiviral constructs or with sulforaphane (5µM) for 8 hours. QRTPCR analysis of 92 cancer-associated miRNAs in treated cells were evaluated. Values represent fold increase over control conditions normalized to RNU6B (ΔCT).

  3. Supplementary Table 2 - Shah et al Supplementary Table 2. miR-125B antagomiR and miR-29B mimic increases AML sensitivity to chemotherapy. THP-1, Kasumi-1, primary CD34+ HSC, AML#25 and AML#27 were transfected with control miRNA, miR-125B antagomiR, miR-29B mimic and miR-125B antagomiR in combination with miR-29B mimic for 24 h before the addition of increasing doses of daunorubicin for 48 h. Cells assessed for viability by Cell Titer-GLO. Table shows the IC50 values for all cells types in response to daunorubicin

  4. Supplementary Table 3 - Shah et al Supplementary Figure 3. Targets for miR-29B and miR-125B

  5. Supplementary Table 4 - Shah et al Supplementary Figure 4. Locations and sequences of putative ARE elements. Primers used in ChIP analysis.

  6. Supplementary Figure 1 - Shah et al Fold miRNA expression over NEG-KD control Supplementary Figure 1. Expression analysis of miRNA levels after transfection with miR-29B mimic and miR-125B antagomir. THP-1 were transfected with control miRNA, miR-125B antagomiR (α125B), miR-29B mimic (29B mimic) and miR-125B antagomiR in combination with miR-29B mimic for 48 h. Also THP-1 cells were transduced with NEG (NEG-KD) and NRF2 (NRF2-KD) targeted miRNA lentiviral constructs for 72 hours. QRTPCR analysis of miR-29B and miR-125B was carried out on all transfected and transduced cells.

  7. Supplementary Figure 2 - Shah et al A 15 miR-125B1 miR-125B P=0.0078 10 Fold RNA expression over CD34+ control P=0.0024 5 0 CD34+ AML Blasts CD34+ AML Blasts B 2.5 miR-29B1 miR-29B 2.0 Fold RNA expression over CD34+ control 1.5 P=0.003 P<0.001 1.0 0.5 0 CD34+ AML Blasts CD34+ AML Blasts Supplementary Figure 2. miR-29B and miR-125B in primary AML. Total RNA was extracted from patient AML blasts (n=18) and CD34+ HSC (n=8), miR-125B (A) and miR-29B (B) RNA expression levels were measured using QRTPCR and compared to miR-125B1 and miR-29B respectively from figure 4 A.

More Related